Defunct Company
Total Trials
8
As Lead Sponsor
As Collaborator
0
Total Enrollment
273
NCT02561234
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Oct 31, 2015
Completion: May 31, 2019
NCT02488044
A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency
Start: Jun 30, 2016
Completion: Feb 28, 2019
NCT02732184
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
Phase: Phase 2
Start: Aug 31, 2016
Completion: Dec 31, 2017
NCT03378531
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency
Start: Dec 7, 2017
Completion: Dec 15, 2022
NCT03371979
Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
Start: Dec 21, 2017
Completion: Jan 1, 2021
NCT03921541
Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency
Phase: Phase 3
Start: Apr 10, 2019
Completion: Jan 27, 2023
NCT05154890
A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency
Start: May 13, 2021
Completion: Apr 21, 2023
NCT05676853
A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency
Start: Apr 4, 2023
Completion: Apr 27, 2023